Abstract
The introduction of anti-vascular endothelial growth factor (VEGF) medications has had a revolutionary impact on the practice of ophthalmology. For many patients with blinding eye conditions like neovascular (also known as wet) age-related macular degeneration (nAMD) and diabetic macular oedema (DMO), intravitreal anti-VEGF agents provided the first hope for meaningful visual recovery. 1 Keane PA Patel PJ Liakopoulos S Heussen FM Sadda SR Tufail A Evaluation of age-related macular degeneration with optical coherence tomography. Surv Ophthalmol. 2012; 57: 389-414 Summary Full Text Full Text PDF PubMed Scopus (179) Google Scholar , 2 Adamis AP Brittain CJ Dandekar A Hopkins JJ Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade. Eye. 2020; 34: 1966-1972 Crossref PubMed Scopus (15) Google Scholar Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trialsVisual benefits with faricimab given at up to 16-week intervals demonstrates its potential to meaningfully extend the time between treatments with sustained efficacy, thereby reducing treatment burden in patients with nAMD. Full-Text PDF Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trialsRobust vision gains and anatomical improvements with faricimab were achieved with adjustable dosing up to every 16 weeks, demonstrating the potential for faricimab to extend the durability of treatment for patients with diabetic macular oedema. Full-Text PDF
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
